SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (2460)7/26/2018 3:58:17 AM
From: Miljenko Zuanic1 Recommendation

Recommended By
Biotech Jim

  Read Replies (1) | Respond to of 3559
 
No clear cut for Roche L-implant PDS in AMD: roche.com and roche.com

Also, US L 1H-2018 sale were 818CHF : 0.96 = $852 --------> 2Q = (425CHF) $438 M , indicating healthy grow for US E 2Q as well!




To: Miljenko Zuanic who wrote (2460)8/2/2018 12:48:22 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
2Q: files.shareholder.com

Eylea US sale (992M) was bit light from my assumption, but it appears that marketing efforts may reverse trend in 2H-2018!

On cemiplimab (REGN2019) note, mono-1L NSCLC, what subjects enrollment increase are they talking? FROM 8-2 update ( clinicaltrials.gov I DO NOT SEE any # increase????!!! What am I missing? Anyone!